FITC Mouse Anti-Human CD206 Antibody (S-R575)

產(chǎn)品型號(hào)：S0B1823

更新時(shí)間：2025-10-08

廠商性質(zhì)：生產(chǎn)廠家

訪問(wèn)量：129

服務(wù)熱線

15855403091

立即咨詢(xún)

產(chǎn)品分類(lèi)

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對(duì)抗體病理/IHC抗體

查看全部產(chǎn)品

如何選擇您的內(nèi)參抗體？

IFN-α4/IFNA4：抗病毒前沿的“快速反應(yīng)部隊(duì)“與疾病調(diào)控的關(guān)鍵分子

EGFR 家族：細(xì)胞生長(zhǎng)的 “指揮官”

產(chǎn)品介紹

CD206, also known as the mannose receptor （MRC1）, is a highly glycosylated type I transmembrane protein primarily expressed on the surface of macrophages and dendritic cells. It plays a crucial role in the innate immune response by mediating the endocytosis and phagocytosis of various pathogens, including bacteria, fungi, and viruses, through its ability to bind to mannan-coated cell walls or envelopes. CD206 is a marker for alternatively activated M2 macrophages, which are characterized by their anti-inflammatory phenotype and are involved in wound healing and immune tolerance. In the context of cancer, tumor-associated macrophages often exhibit high levels of CD206, contributing to tumor progression by promoting immunosuppression, metastasis, and angiogenesis. This makes CD206 a potential target for cancer immunotherapy, as its activation can enhance both adaptive and innate antitumor immune responses.

上一個(gè)：S0B1824FITC Mouse Anti-Mouse CX3CR1 Antibody (S-R597)